Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

NCT06962332 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment
Moderate Hepatic Impairment

Interventions

DRUG: Zanzalintinib

Sponsor

Exelixis